Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS® Grass tablets for patients with grass pollen-induced allergic rhinoconjunctivitis, a phase III study

Trial Profile

Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS® Grass tablets for patients with grass pollen-induced allergic rhinoconjunctivitis, a phase III study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2014

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Therapeutic Use
  • Acronyms SMART-10
  • Sponsors Lofarma S.p.A
  • Most Recent Events

    • 09 Nov 2013 Planned end date changed from 26 Nov 2013 to 26 Jan 2014 as reported by European Clinical Trials Database record.
    • 07 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top